Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels(132 visite) Del Vecchio S, Stoppelli MP, Carriere MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salvatore M
Cancer Res (ISSN: 0008-5472, 1538-7445, 1538-7445electronic), 1993 Jul 1; 53(13): 3198-3206.
Tipo di articolo: Journal Article,
Impact factor: 8.426, Impact factor a 5 anni: 8.036
Parole chiave: Cell Surface Receptor, Urokinase, Adult, Article, Autoradiography, Breast Carcinoma, Clinical Article, Controlled Study, Enzyme Analysis, Human, Human Cell, Human Tissue, Priority Journal, Prognosis, Aged, Breast Diseases, Breast Neoplasms, Cell Division, Cell Membrane, Female, Lymphatic Metastasis, Middle Age, Neovascularization, Pathologic, Support, Non-U.S. Gov, Tissue Distribution, Tumor Cells, Cultured, Urinary Plasminogen Activator, Non-U. S. Gov,
Medicina Nucleare, Univ. degli Studi Federico II, Facoltà de Medicina, Via S. Pansini 5, 80301 Naples, Italy Istituto Nationale Tumori, Naples, Italy Ist. Internazionale Genet. e Biofis., Naples, Italy
We measured the tissue concentration of human urokinase receptor (nPAR) in 22 breast carcinomas and 9 benign breast lesions using in vitro quantitative autoradiography. Tissue sections were incubated with increasing concentrations of 125I-pro-urokinase in the presence or absence of unlabeled competitor. Breast carcinomas were found to contain 5 times more uPAR than benign breast lesions with respect to their protein content [523 ± 72 versus 108 ± 20 (SE) fmol/mg (P < 0.001)]. Simultaneous quantitation of urokinase (uPA) by immunoenzymatic assay on tissue extracts from the same specimens showed that breast carcinomas also contain 19 times more uPA than benign tumors (611 ± 134 versus 32 ± 8 fmol/mg) (P < 0.01). The reliability of quantitative autoradiography measurements was confirmed by uPAR cross-linking assay on membrane fraction from either U937 histiocytic lymphoma cells or breast carcinomas and immunoperoxidase staining with an anti-uPAR antibody on tumor sections. Also, immunoperoxidase staining with an anti-uPA monoclonal antibody showed that uPA is indeed localized on the plasma membrane of epithelial tumor cells in confined areas of breast carcinomas whereas cells from benign breast lesions were devoid of uPA under the same experimental conditions. In conclusion, our findings support the hypothesis that uPAR plays a central role in the acquisition of an invasive phenotype and favor its potential use as a prognostic factor in patients with breast carcinoma.
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(92 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, Von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, De Jong M * The EEE project(234 visite) Proc Int Cosm Ray Conf Icrc Universidad Nacional Autonoma De Mexico, 2007; 5(HEPART2): 977-980. Impact Factor:0 DettagliEsporta in BibTeXEsporta in EndNote